Skip to product information
1 of 2

FAAH1 Recombinant Rabbit mAb

FAAH1 Recombinant Rabbit mAb

Catalog Number: S0B60816 Application: WB Reactivity: Hu, Ms Conjugation: Unconjugated Brand: Starter
Price:
Regular price $100 USD
Regular price Sale price $100 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Rabbit
Antigen FAAH1
Synonyms Fatty-acid amide hydrolase 1; Anandamide amidohydrolase 1; Fatty acid ester hydrolase; Oleamide hydrolase 1; FAAH
Immunogen Recombinant Protein
Location Cytoplasm, Cytoskeleton
Accession O00519
Antibody Type Recombinant mAb
Isotype IgG
Application WB
Reactivity Hu, Ms
Positive Sample SK-OV-3, HT-29, LnCaP, mouse cerebellum, mouse kidney, mouse liver
Purification Protein A
Concentration 2 mg/ml
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS, 40% Glycerol, 0.05% BSA, 0.02% sodium azide

Stability & Storage

12 months from date of receipt / reconstitution, -20 °C as supplied

Dilution


application dilution species
WB 1:1000 Hu, Ms

Background

FAAH1 (fatty acid amide hydrolase 1) is an integral membrane protein localized to the endoplasmic reticulum/Golgi membrane, belonging to the amidase signature family and functioning as a homodimer. The human protein consists of 579 amino acids with a molecular weight of approximately 63 kDa. Its core catalytic function is to hydrolyze endogenous cannabinoid anandamide, the sleep-inducing substance oleamide, and various other bioactive fatty acid amides, generating the corresponding fatty acids and amines and thereby terminating the physiological actions of these lipid signaling molecules; its active site possesses a unique Ser-Ser-Lys catalytic triad, in which Ser241 is the nucleophilic residue. FAAH1 is highly expressed in the brain, small intestine, pancreas, skeletal muscle, and testis, and by regulating the levels of endogenous cannabinoids such as anandamide, it participates in the modulation of pain perception, mood, inflammation, and cognitive function. At the pathological and therapeutic level, FAAH1 is a well-established drug target for neuropathic pain, anxiety, and inflammation, and its inhibitors exhibit analgesic, anxiolytic, and anti-inflammatory phenotypes in preclinical models; in addition, studies from 2024–2025 further indicate that pharmacological inhibition of FAAH1 can attenuate neuroinflammation, reduce β-amyloid levels, and reverse cognitive deficits in mouse models of Alzheimer's disease, suggesting its potential as a disease-modifying therapy for neurodegenerative diseases. Notably, humans also possess an isoenzyme, FAAH2, which shares only about 20% sequence identity with FAAH1, and the FAAH2 gene is absent in mice and rats, so this difference must be considered when extrapolating across species.

Picture

Western Blot

WB result of FAAH1 Recombinant Rabbit mAb
Primary antibody: FAAH1 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: SK-OV-3 whole cell lysate 25 μg
Lane 2: HT-29 whole cell lysate 25 μg
Lane 3: LnCaP whole cell lysate 25 μg
Secondary antibody: Goat Anti-Rabbit IgG (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 63 kDa
Observed MW: 60 kDa
This blot was developed with high sensitivity substrate

WB result of FAAH1 Recombinant Rabbit mAb
Primary antibody: FAAH1 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: mouse cerebellum lysate 25 μg
Lane 2: mouse kidney lysate 25 μg
Lane 3: mouse liver lysate 25 μg
Secondary antibody: Goat Anti-Rabbit IgG (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 63 kDa
Observed MW: 60 kDa